Thalidomide and lenalidomide in the treatment of multiple myeloma
- 1 July 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (11) , 1612-1622
- https://doi.org/10.1016/j.ejca.2006.04.004
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Pharmacokinetics and Pharmacodynamics of Thalidomide in HIV Patients Treated for Oral Aphthous Ulcers: ACTG Protocol 251The Journal of Clinical Pharmacology, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971